Related Links

News

New data published on anti-cancer isoquinolinamine derivatives

19 October 2010

Rexahn Pharmaceuticals have announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal of Medicinal Chemistry.

In the study, various substituted 3-aryl-1-isoquinolinamine derivatives were shown to have excellent cytotoxicity against eight different human cancer cells (breast, prostate, colon, ovary, kidney, pancreas, glioblastoma and melanoma).

‘In this second published study, we further establish that isoquinolinamine derivatives, such as our anti-cancer compound RX-8243 – a new chemical entity – are potent anti-cancer compounds that have the potential to be developed into chemotherapeutic agents,’ said Rick Soni, President of Rexahn.

These derivatives were synthesized and evaluated through the constructed quantitative structure–activity relationship (QSAR) model and in vitro cell studies. The cytotoxic activities of new designed compounds are calculated using the constructed QSAR model and compared with actual cytotoxic data using the synthesized compounds.

Last month, Rexahn announced the publication of new preclinical data in Bioorganic & Medicinal Chemistry Letters demonstrating that RX-8243, an isoquinolinamine analogue, significantly inhibits the growth of human cancer cells, including paclitaxel (Taxol®)-resistant HCT-15 human colorectal cancer cells and the growth of tumour in an in vivo model of nude mice injected with paclitaxel-resistant HCT-15 human colorectal cancer cells.

Further reading

Yang, S.H. et al. (2010) Development of 3-aryl-1-isoquinolinamines as potent antitumor agents based on CoMFA. European Journal of Medicinal Chemistry 45, 5493–5497

Share this article

Comments

Kirsty Strawbridge said

10 November 2010
Thanks for your comment, navinrathi. The article can be found here: doi:10.1016/j.ejmech.2010.08.042.

navinrathi said

09 November 2010
i cant find any refrences from refrence given at the bottom of this article (Yang,s.h. et al).can u sujjest me from where i get this article.THANK you

Note: The majority of comments posted are created by members of the
public. The views expressed are theirs and unless specifically stated are not those
Elsevier Ltd. We are not responsible for any content posted by members of the public
or content of any third party sites that are accessible through this site. Any links
to third party websites from this website do not amount to any endorsement of that
site by the Elsevier Ltd and any use of that site by you is at your own risk. For
further information, please refer to our Terms & Conditions.

Comment on this article

You must be registered and logged in to leave a comment
about this article.

Members' Login

Our website uses cookies. Cookies enable us to provide the best experience possible and help us understand how customers
use our website.Our site won't work without them. By continuing to use our website you accept our use of cookies.
Find out more about cookies×